Trials / Completed
CompletedNCT04739306
Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
A Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 348 (actual)
- Sponsor
- Celltrion · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in comparison with Eylea in Patients with Diabetic Macular Edema
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CT-P42 | 2mg/0.05 mL by Intravitreal injection |
| BIOLOGICAL | Eylea | 2mg/0.05 mL by Intravitreal injection |
Timeline
- Start date
- 2021-07-22
- Primary completion
- 2022-10-14
- Completion
- 2023-04-24
- First posted
- 2021-02-04
- Last updated
- 2023-12-05
- Results posted
- 2023-12-05
Locations
1 site across 1 country: Slovakia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04739306. Inclusion in this directory is not an endorsement.